Industry Today Logo

Published Fri, Dec 15th 2017

Global Viral Inactivation Market to Record a Sluggish CAGR of 7.4% between 2017 and 2025

As per a report by Transparency Market Research, the global viral inactivation market will likely rise at a healthy 7.4% during the period between 2017 and 2025. Rising at this rate, the market will likely become worth US$5.736 bn by 2025 from US$3.05 bn in 2016.

Posted via Industry Today. Follow us on Twitter @IndustryToday


A popular strategy with savvy players in the global market for viral inactivation trying to bolster their positions is the thrust on acquisitions. Besides, they are also investing heavily in research and development to come up with new products in response to various requirements for treating diseases. A dominant players in the market, namely Merck & Co., Inc., is seen to have a stronghold across nations worldwide.  

At the forefront of driving growth in the global market for viral inactivation is the rising approvals of new drugs, rules pertaining to viral safety of biologics, and the proliferation of the biologics and biosimilars industry. Besides, the growing instances of various infectious diseases and growing application of biosimilars therapeutic treatment for a range of diseases are also positively impacting the market.

Request A Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=21497

Proving counterproductive to the market, on the downside, is the high costs involved in developing and manufacturing biologics and biosimilars products and also the high price of equipment for viral inactivation. However, new types of viruses needing vaccinations to be developed against them spells new opportunities for the market.

A report by Transparency Market Research predicts the global viral inactivation market to expand at a healthy 7.4% CAGR from 2017 to 2025 to become worth US$5.736 bn by 2025 from US$3.05 bn in 2016.

Depending upon the type of method, the global viral inactivation market can be divided segmented into chemical, radiation, and others such as pasteurization and dry and moist heat treatment. Of them, the chemical method leads the market with maximum share as it is a robust and effective method of inactivation of different types of viruses. It is also cost-effective, safe, and brings about a high degree of purity of sample. The chemical method is further sub-segmented into solvent detergent method, use of alkylating agent method, and pH concentration method. The solvent detergent method, among them, is projected to account for largest market share by the end of 2025.  

In terms of growth rate, however, the radiation method for viral inactivation is expected to outpace all others on account of the rising adoption of the method in blood centers in developed nations. The UV radiation method has been tested and developed for viral inactivation of blood and blood components at blood centers and at commercial manufacturing facilities.

From a geographical standpoint, North America currently holds a sway over the global market on account of a robust biopharmaceutical industry, swift uptake of newer viral inactivation methodologies, rising demand for blood and blood components for transfusion therapy, and strict regulatory guidelines for the viral safety of biologics products. By growing at a CAGR of 7.2% in the forecast period, the market will likely become worth US$2.31 bn by 2025.

However, North America is slated to lose some of its market share to Asia Pacific, which is predicted to expand at maximum pace. The report by TMR projects the viral inactivation market in the region to clock a CAGR of 7.9% from 2017 to 2025. The region’s growth will be primarily powered by countries of South Korea, Japan, and Australia which have strict rules in place for purity of biologics and biosimilars products and also by China, India, and Malaysia having a booming biopharmaceutical industry.

Some of the dominant players in the global market for viral inactivation are Shandong Weigao Group Medical Polymer Company Limited, Sartorius AG, Cerus Corporation, Macopharma SA, and Terumo BCT, Inc.

Request to view table of content @ https://www.transparencymarketresearch.com/report-toc/21497


Contact information

Rahul Singh
Persistence Market Research Pvt. Ltd.
3rd Floor, 207 Regent Street,

London
W1B 3HH,
6465687751

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

Visit www.industrytoday.co.uk to publish and distribute news from your Industry. Optimised press releases appear in Google News. Connect with us via the social networks Twitter, Facebook, LinkedIn, Google+ and Pinterest